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abstract
The EORTC Children’s Leukemia Group (CLG) is a spin-off from the EORTC
Hemopathies Working Party (adults and children). After a decade of collaboration in
the adult-pediatric group it became clear that there was not only a large difference
in cure rates between children and adults, but many chemotherapeutic-toxic borders
were substantially different. During the following decade the CLG was not only a
witness of a very exciting battle against childhood leukemia, but it also contributed
substantially to better cure rates for these diseases.
The main activity of the CLG was concentrated on the ﬁeld of acute lymphoblastic
leukemia (ALL). Fine tuning of treatment elements using the BFM design as a
backbone has been done very successfully over the past decades. The CLG has many
achievements, and the major ones include: the 58831 trial showing the superﬂuity of
the prophylactic Central Nervous System (CNS) radiotherapy in ALL patients when
a adequate systemic and CNS directed chemotherapy is ascertained. The 58881 trial
demonstrated that the assessment of minimal residual disease (MRD) at completion
of induction in ALL is a key step in the process to categorizing and allocating patients
into different risk groups, and that MRD is a powerful and independent prognostic
factor. This same 58881 trial showed the clear difference in efﬁcacy of different
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asparaginases resulting in an optimization of the use these drugs and a revival of
interest for the asparaginases in the treatment of ALL.
In the near future the CLG will focus mainly on translational research projects
and innovative biologically targeted treatment approaches, on collaborations with
other children’s leukemia groups in intergroup studies, and on the evaluation of the
long-term outcome of childhood cancer survivors.
© 2012 European Organisation for Research and Treatment of Cancer.
1. History of the EORTC Children’s Leukemia
Group (CLG)
Among all types of childhood cancers, leukemias and
lymphomas account for approximately 40% of the
cases. The most common subtype of leukemia in
children is acute lymphoblastic leukemia (ALL), and the
lymphoblastic origin is also prominent in non-Hodgkin
lymphomas (NHL) of childhood.
Survival has increased for all childhood cancers since
the late 1960s, but by varying amounts and at different
points in time. The most spectacular improvement
in the recent 50 years has been seen in the cure
rate of the lymphoblastic malignancies (leukemia and
lymphoma). For childhood ALL, overall survival (OS)
rates were less than 5% before 1970 but nowadays
with contemporary risk-directed therapy have reached
a 5-year Event-Free Survival (EFS) and OS of 80−85%
and 90%, respectively. 1,2 Also in childhood NHL the
cure rates have risen dramatically to reach a 5-year
OS rate of 90%. These improvements are not linked
to more effective drugs but rather to the accurate use
of already existing drugs (effective combinations), to
an improved understanding of the natural behavior of
the disease (sanctuaries protecting cancer cells), to the
ﬁne-tuning of delivering chemotherapeutic interventions
(late intensiﬁcation, maintenance), and to a better
identiﬁcation of prognostic factors. The use of stem cell
transplantation has also improved the outcome of these
young patients with very high risk features.
The EORTC Children’s Leukemia Group (CLG) is a
spin-off from the EORTC Hemopathies Working Party
(adults and children) and has been right in the
middle of the exciting battle against this childhood
cancer. The Hemopathies Working Party started its
activities in 1971. Between 1971 and 1978, patients
from Belgian and French centers were registered in the
ﬁrst ALL trial 58741. This study evaluated in particular
two types of consolidation therapy (polychemotherapy
versus a methotrexate-based consolidation therapy)
and two types of maintenance therapy (chemotherapy
versus immunotherapy). Especially the inferiority of the
immunotherapy as maintenance therapy was striking. 3
Another important conclusion of this study was the
large difference in EFS and OS of children and adults.
In the beginning of the 1980’s, very promising results
in the treatment of ALL were published by three
German centers (Berlin–Frankfurt–Munster [BFM], led
by H. Riehm). 4 Consequently, Belgian pediatric centers
and several French centers decided to create their own
group within the EORTC and started a study with a
BFM treatment backbone. 5,6 Afterwards, centers from
Portugal joined the CLG. Between 20 and 30 hospitals
(most of them university hospitals or afﬁliated with
a university) are now working together in the ﬁeld of
pediatric hemato-oncology, especially in the area of acute
leukemias.
The main activity of the CLG was concentrated in the
ﬁeld of ALL. Fine-tuning of treatment elements within
the backbone of the BFM design has been done very
successfully during the past decades.
Due to the much smaller number of pediatric patients
with acute myeloid leukemia (AML), the contribution of
the CLG to possible improvements in the treatment of
this malignancy has been much more limited than for
ALL or NHL. In the past three decades, the CLG has
witnessed signiﬁcant improvement in the outcomes of
pediatric patients with AML. 7,8 Although the progress
was less spectacular, EFS and OS were above 50% and
60%. In contrast to the prolonged, low-intensity regimens
used for pediatric ALL, high-intensity therapy is critical
in treating AML successfully.
From 1983 until now, nine randomized clinical
therapeutic trials have been successfully conducted by
the CLG: ﬁve in ALL, 3,5,9−15 two in NHL, 16 and two
in AML. 7,8,17 The CLG has also actively participated in
several retrospective and prospective intergroup studies
and trials in ALL and AML. In the following section
we describe three of the CLG’s most successful studies
in ALL.
2. Three major achievements of the CLG during
the past decades
2.1. Comparison of Escherichia coli-asparaginase with
Erwinia asparaginase in the treatment of childhood lymphoid
malignancies: results of the phase III randomized EORTC
58881 trial. − M. Duval et al., 2002 9
L-Asparaginase is an antileukemic drug used as part
of the treatment for lymphoblastic malignancies in
children since more than four decades. Asparaginases
are used for remission induction and intensiﬁcation
Open access under CC BY-NC-ND license.
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treatment in pediatric ALL-regimens. Three asparaginase
preparations are available: the native asparaginase
derived from Escherichia coli (E. coli asparaginase), a
product isolated from Erwinia chrysanthemi (i.e., Erwinia
asparaginase) and a pegylated form of the E. coli enzyme
(PEG-asparaginase). Only in the last decade has the
importance of asparaginase in the treatment of ALL
become clear, and it is now believed to be a cornerstone
of treatment protocols for ALL. Most clinical evidence
in the use of asparaginase is based on non-randomized
trials. More than 20 years ago, it was suggested that there
was a similar efﬁcacy between native E. coli asparaginase
and Erwinia asparaginase, with a less toxic pattern for
the E. chrysanthemi formulation.
In 1988 the CLG started a trial using a BFM-like
protocol and compared the efﬁcacy and toxicity of E. coli
asparaginase (E coli-Asp) versus Erwinia asparaginase
(Erwinia-Asp) in a randomized fashion in children with
ALL and NHL. A total of twelve doses of 10,000 IU/m2 each
were planned: eight during induction (protocol IA) and
four during reinduction (protocol II). Between November
1990 and October 1993, 700 patients were randomized
in this trial: 354 in the E coli-Asp arm and 346 in
the Erwinia-Asp arm. A similar number of patients
in both groups received all the planned doses during
protocols IA and II. Coagulation abnormalities were more
often observed in the E coli-Asp arm at induction:
30.2% versus 11.8%; odds ratio, 3.20; P< 0.0001. The
incidence of other toxicities was similar in the two
treatment groups. In the Erwinia-Asp arm, more patients
failed to achieve complete remission after completion
of protocol IA (4.9% versus 2.0%; P=0.04) and the
relapse rate was higher, leading to shorter EFS (hazard
ratio, 1.59; 95%conﬁdence interval, 1.23–2.06; P = 0.0004).
The estimate of EFS rate at 6 years was 59.8% (standard
error [SE] = 2.6%) versus 73.4% (SE=2.4%). OS rate at
6 years was also lower in the Erwinia-Asp arm at 75.1%
(SE=2.3%) versus 83.9% (SE=2.0%), P = 0.002.
This trial was the ﬁrst to demonstrate the superior
clinical efﬁcacy of E coli-Asp versus Erwinia-Asp during
induction and reinduction in a randomized fashion
and established the basis for subsequent studies. As
a result of this, E coli-Asp has become a universal
component of ALL therapy and is used in every pediatric
regimen for ALL. Moreover, the clinical results observed
here revealed a positive correlation with laboratory-
based studies conducted by other groups, conﬁrming the
important relevance of these achievements.
More recently it also became clear that clinical
hypersensitivity reactions and silent inactivation due
to antibodies against E coli-Asp lead to inactivation of
E coli-Asp in up to 60% of cases. Typically, patients
exhibiting sensitivity to one formulation of asparaginase
are switched to another to ensure they receive the most
efﬁcacious treatment regimen possible.
Erwinia-Asp is now used only as a second- or third-line
treatment in European and US protocols. Nevertheless,
Erwinia-Asp still plays an important role in those
patients unable to tolerate native forms of asparaginase
and signiﬁcantly contributes to the good results obtained
in this group of patients. New formulations of this
drug, such as the pegylated form of Erwinia, are already
under preclinical study and may have a potential role
in the coming years. PEG-Asparaginase is on its way to
become the asparaginase of choice. Its potential beneﬁts
compared to the native E coli are very promising. Current
randomized trials are aiming to answer this question in
the ﬁrst-line treatments.
2.2. Clinical signiﬁcance of minimal residual disease (MRD)
in childhood ALL: Results of the phase III EORTC 58881
trial − H. Cave´ et al., 1998 18
Evaluation of response to treatment in children with ALL
has classically been performed based on morphological
ﬁndings. The extent of clearance of leukemic cells from
the blood or bone marrow is an independent prognostic
factor in ALL. In an attempt to go beyond the limits
of the microscope, biologists and hematologists in the
1990’s developed new techniques able to identify traces
of disease that escaped the accuracy of the human eye.
The CLG prospectively assessed the prognostic value of
the amount of detectable residual disease at several
time points during the ﬁrst six months after complete
morphological remission of childhood ALL had been
induced.
A total of 246 patients with ALL enrolled in the EORTC
58881 trial. Rearrangements of the T-cell receptor genes
TCRg and TCRd or those for the gene for immunoglobulin
heavy chain (IgH) were characterized at the time
of diagnosis. A competitive PCR assay was used to
quantitate the residual blasts. Two reference laboratories
centralized the samples for study. Of the 246 patients,
178 (72%) were monitored for residual disease. These
178 patients were similar to the 654 patients in the
non-participating centers included in the trial regarding
prognostic factors and duration of remission. Median
follow up was 38 months. The presence or absence
(<10−4) and level of residual leukemia were signiﬁcantly
correlated with the risk of early relapse at each of the
times studied (P< 0.001). PCR measurements identiﬁed
patients at very high risk for relapse after the completion
of induction therapy (those with 10−2 residual blasts
per 2×105 mononuclear bone marrow cells have a risk of
relapse 16 times higher than those with <10−2 residual
blasts) or at later time points (those with 10−3 have
a risk of relapse 15−22 times higher than those with
<10−3 residual blasts). Multivariate analysis conﬁrmed
that presence/absence and level of residual disease were
the most powerful independent prognostic factors.
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Presence of MRD was found to have a negative impact
on duration of remission and OS in patients who,
morphologically, reached complete remission. Patients
who did not completely clear the disease after induction
or later in the treatment did signiﬁcantly worse than
those responding to conventional therapy. Nowadays,
MRD evaluation is a key step in the early process
to categorize and allocate patients into different risk
groups. MRD analysis was an important step forward
to a more personalized medicine, clearly identifying
those patients who could beneﬁt from a more intense
treatment. In the subsequent EORTC ALL trial (58951),
those with a high level of MRD (10−2) at end of induction
were switched to a very high risk protocol leading to
better results in terms of EFS and OS.
2.3. Comparison of high-dose methotrexate (MTX) +/−
subsequent central nervous system (CNS) irradiation to
prevent CNS relapse in medium and high risk patients
with ALL: results of the phase III EORTC 58831/2 trials −
E. Vilmer et al., 2000 10
Treatment for ALL must take into account the possible
leukemic attenuation of the so-called sanctuary disease
sites like CNS and testes. Although only 3% of children
with ALL have evidence of leukemia in the central
nervous system at the time of diagnosis, leukemia will
become evident in this region in 50−70% of children
who don’t receive prophylactic or preventive treatment.
Treatment and clinical control of CNS leukemia has
always been a therapeutic challenge in childhood ALL.
For more than four decades, CNS irradiation has been
successfully used in children with ALL as part of a
multimodal treatment in order to treat and prevent the
recurrence of the disease in the CNS. Cranial irradiation
is indeed a very effective form of CNS-directed therapy,
but its efﬁcacy is offset by substantial rates of secondary
neoplasms, endocrinopathy, neurocognitive dysfunction,
and neurotoxicity. These deleterious side effects and
long-term neurological deﬁcits observed in the survivors
prompted all investigators to ﬁnd other ways to
reduce the risk of CNS relapse and avoid the use of
radiotherapy.
The CLG assessed whether the deletion of CNS
irradiation in medium and high risk ALL patients
receiving systemic high doses of MTX may be done
without compromising the therapeutic results. Medium-
and high-risk ALL patients were randomized into two
groups to receive four high doses of MTX (2.5mg/m2)
during induction and consolidation given concomitantly
with intrathecal MTX with or without subsequent cranial
radiotherapy (age adapted doses). Standard-risk patients
also received four doses of MTX as prophylaxis for
CNS relapse, at a lower dosage (0.5mg/m2), and no
cranial irradiation. A total of 735 eligible patients,
standard or medium–high risk, were included in the
analysis. Of those, 183 medium- or high-risk patients
were randomized for the question. High-dose MTX alone
was as effective as high-dose MTX followed by cranial
radiotherapy in terms of disease-free survival (DFS),
isolated CNS relapse rate and isolated or combined CNS
relapse rate. The 6-year DFS rates were 68% (without
irradiation arm) and 66% (with irradiation arm). The
isolated CNS relapse rates were respectively 7% and 7% in
those without and with cranial irradiation and the CNS
relapse rates were respectively 9% and 15%. For the later
endpoint, the estimated hazard ratio (with irradiation
versus without irradiation: control group) was 0.57, its
95% conﬁdence interval was 0.24–1.35, which does not
include 2.12 [hazard ratio corresponding to an increase in
CNS relapse rate at six years from 10% (with irradiation)
to 20% (without irradiation)].
The results of this study showed that CNS radiotherapy
could be safely spared in these groups of patients
when replaced by adequate systemic and CNS-directed
chemotherapy. Since then, EORTC trials 58881 and 58951
omitted CNS irradiation successfully even in patients at
high risk of CNS relapse. 15 Hence, most contemporary
pediatric protocols limit the use of this treatment
modality to patients who are at particularly high risk for
CNS relapse, but there is a clear tendency for most groups
to move in the same direction (no radiotherapy) which
has been taken by the CLG since 1988. Children with ALL
can now be cured with a high rate of success and avoid
the undesirable acute and long-term side effects of CNS
radiotherapy (especially secondary neoplasm, endocrine
and neurocognitive disorders).
3. The future of the CLG
The current rates for cure in pediatric ALL are high.
Most of the pediatric hemato-oncologists experience
that the limits of chemotherapeutical treatment seem
to have been reached in many children suffering from
ALL. Optimal use of the antileukemic agents, molecular
genetic analyses of leukemic cells, pharmacodynamic
studies of drugs, pharmacogenetic studies of the
host’s drug-metabolizing enzymes, drug transporters,
and drug targets are however providing a rational and
scientiﬁc basis for further improvement of treatment
efﬁcacy as well as for the reduction of complications.
Also early treatment response, as deﬁned by the
measurement of minimal residual disease, which reﬂects
both the drug responsiveness of leukemic cells and
host pharmacodynamics/pharmacogenomics, is the very
reliable prognostic indicator for gauging the intensity of
treatment.
3.1. Translational research (TR)
Although impressive high cure rates have been achieved
in pediatric cancer treatment, there is still controversy
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about the optimal treatment strategy for childhood ALL,
especially regarding the risk-directed therapy. The aims
of the risk-directed therapy are to avoid overtreatment
for children with good prognosis, in order to reduce as
much as possible the acute and the long-term toxicity,
and to give more intensive therapy for children with
worse prognosis. Nevertheless, with the currently used
prognostic factors, there is still a risk for patients with
good prognosis to be overtreated and for patients with
bad prognosis to be undertreated. Further prognostic
factors reﬁning the risk-group classiﬁcation should
therefore be looked for. Statistical evaluation of cytoge-
netic, molecular, immunological, and MRD data, which
have been collected prospectively in the framework
of the large EORTC 58951 trial, will be done in the
near future, once the randomized questions of this
study (value of dexamethasone versus prednisone in
induction and of prolonged versus conventional duration
of E coli-Asp therapy during consolidation and late
intensiﬁcation) will be assessed. In addition, innovative
biologically targeted treatment approaches are needed
for patients with high risk criteria and for those with
refractory or relapsed disease.
A better understanding of the ALL biology is thus
needed and will help to identify reﬁned prognostic
factors and to develop novel molecular and cellular
therapeutic strategies. 19−22 This can be reached by
centralizing the collection of clinical data in parallel with
sampling and processing and storing biological samples
according to well-deﬁned standard operating procedures
(biobanking). This centralized procedure will allow the
storage of a large number of quality-controlled biological
samples and the collection of relevant associated clinical
data. The standardized and large collection of biological
and clinical data will also give the possibility to develop
well-designed TR projects, even for small ALL subgroups,
the results of which will allow the design of new clinical
and biological research projects.
Applied biosciences using advanced biochemical,
genetic, and immunological knowledge is a very rapidly
moving ﬁeld. Technologies such as transcript proﬁling or
genome-wide analyses on microarray are now broadly
used in TR and require DNA and/or RNA prepared
according to convenient and standardized technical
procedures. Therefore, samples already banked are not
always suitable for all studies. This problem is clearly
illustrated by miRNA studies (extraction procedures are
needed that keep small-sized RNA). For patients with
newly diagnosed disease, the major trends in the coming
years are to further adapt the therapy based on better
deﬁned prognostic/predictive factors.
In this context, we started a prospective biobanking
study (EORTC trial 58081) with associated important
TR projects. Through a better understanding of molecular
mechanisms underlying leukemogenesis, they will allow
further identiﬁcation of new biomarkers, deﬁnition of
speciﬁc subgroups within ALL, and the development
of targeted therapies. This will help to prepare fu-
ture biology-based randomized questions speciﬁcally
oriented to particular subgroups.
3.2. Collaborations with other children leukemia groups in
Intergroup studies
In Europe, most cooperative groups for the treatment of
acute leukemia in children are organized on a national
basis. The CLG, albeit presently in French, Belgian and
Portuguese centers, is open to pediatric hematology-
oncology centers or Groups from all countries and it
also favors increased collaborations with other Groups.
Since the EU directives have changed the conduct of
clinical research trials in Europe, the role of the CLG
in coordinating international studies can become more
important as a result of the knowledge and experience
of EORTC Headquarters in this domain.
The CLG was one of the founding members of the
international ALL I-BFM-SG (International BFM Study
Group) and of the Ponte di Legno Group working
group. These collaborations have led to substantial
progress in leukemia research. By pooling data from all
major study groups, it has been possible to improve
the understanding of the biology and heterogeneity
of subtypes of the disease and to acquire insight
into their optimal therapy. 23−25 The collaboration has
mainly focused on small subgroups of ALL patients:
Philadelphia-chromosome positive, 26 infants, 27 induc-
tion failures, hypodiploidy, 28 t(4;11), 29 iAMP21, t(17;19),
Down Syndrome (each one 1−4% of the whole group).
In these small subgroups, recommendations or clinical
trials can only be launched in a large intergroup study.
The CLG has contributed also to overviews performed
in the framework of the Children ALL Collaborative
Group by the Oxford team, on the value of cranial
radiotherapy, additional treatment during induction–
consolidation, and additional treatment (e.g. pulses) in
maintenance. 30
3.3. Long-term outcome of childhood cancer survivors
As cure rates in ALL and NHL improve, more children
experience late toxicity from their therapy, sometimes
leading to late excess mortality. The increasing number
of survivors has prompted studies of the long-term
health consequences of treatments for childhood cancer.
It is clear that damage to the organ systems of children
caused by chemotherapy and radiation therapy may not
become clinically evident for many years.
The most common late toxic effects are cardiotoxicity,
growth retardation, obesity, endocrine disorders, fertility
impairment, central nervous system effects, and sec-
ondary neoplasms. Assessment of the long-term survival
of children cured of cancer must consider also their
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social outcome. Age at diagnosis, sex, current age, socio-
economic status, and life transitions may affect social
outcome of childhood cancer survivors. The treatment
type or intensity may also affect psychosocial functions.
Based on the large CLG experience we have the
opportunity to analyze a large series of childhood
ALL and NHL survivors with long-term follow up and
treated according to well-deﬁned protocols. 3,10,15 It will
also allow comparisons between treatment arms (e.g.
with or without cranial radiotherapy) and risk groups.
A better knowledge of the long-term follow up and the
late adverse events is indeed essential in view of the
improvements of cure rates.This would be useful in order
to set up a speciﬁc and standardized long-term follow up
for patients treated for childhood ALL and NHL in EORTC
studies. It would also help to further adapt therapy in
order to avoid overtreatment of low-risk patients and
therefore reduce as much as possible the occurrence of
late effects in this population.
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